Prostate Cancer | China In-Depth | 2020
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence of prostate cancer throughout China. The drug-treatment rate has increased over the last few years owing to strong uptake of novel premium-priced therapies and these drugs’ inclusion in the NRDL in the 2017 update, especially abiraterone (Janssen’s Zytga). Most recent drug approvals in China (e.g., enzalutamide [Astella’s Xtandi], apalutamide [Janssen’s Erleada], degarelix [Ferring Pharma’s Firmagon] underscore manufacturers’ focus on the prostate cancer therapy market in China. Multilabel expansions of marketed drugs to new patient populations are expected.
- How large is China’s drug-treatable prostate cancer population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s prostate cancer market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the market access considerations for key therapies in the prostate cancer pipeline in China? What sales/uptake could these agents secure in prostate cancer? What are interviewed experts’ opinions of these therapies?
- What are the key drivers and constraints in the Chinese prostate cancer therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
RELEASE DATE
December 2020
GEOGRAPHY
China
PRIMARY RESEARCH
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with medical oncologists and urologists. Supported by survey data collected for this and other DRG research.
EPIDEMIOLOGY
Diagnosed incidence of prostate cancer in urban versus rural China; clinically relevant and market-relevant, drug-treatable populations.
FORECAST
10-year, annualized, drug-level sales and patient shares of key prostate cancer agents through 2029, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III/PR: 10+ drugs; Phase II: 1 drug
